DelveInsight’s ‘Multiple System Atrophy (MSA)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The MSA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM MSA market size from 2017 to 2030. The Report also covers current MSA treatment practices, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.
Multiple System Atrophy (MSA) Overview
Multiple System Atrophy (MSA), formerly known as Shy-Drager Syndrome, is a rare, degenerative neurological disorder affecting the body's involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The term multiple system atrophy was first introduced in the medical literature in 1969. It encompasses three presentations of a single disease formerly thought to be separate disorders, specifically Shy-Drager syndrome (which emphasized autonomic dysfunction), striatonigral degeneration (which emphasized parkinsonian symptoms), and sporadic olivopontocerebellar atrophy (which emphasized cerebellar symptoms).
MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). A patient diagnosed with MSA-P may over time appear to have MSA-C and vice versa, so these categorizations are not always set in stone.
Multiple System Atrophy (MSA) Diagnosis
A detailed clinical evaluation, including medical history, physical, and neurological examinations with special attention to gait, coordination, and muscle tone, is the most important step in evaluating a patient with suspected MSA.
Continued in the report…..
Multiple System Atrophy (MSA) Treatment
There is no specific treatment for MSA. Treatment is aimed at controlling the symptoms of the disease with the help of supportive therapies (physiotherapy, occupational therapy, and speech therapy) and treatment of autonomic symptoms. Drugs that are used to treat people with Parkinson’s disease, most notably levodopa, may also be prescribed for individuals with MSA. However, the effectiveness of such medications varies significantly among affected individuals. In many cases, individuals do not respond or respond poorly to such therapy.
Approximately one-third of affected individuals respond to levodopa therapy. However, in most cases, the effectiveness of this therapy decreases over time. In addition, these drugs must be used with caution because they may lower blood pressure.
Certain medications are designed to treat certain symptoms. There are some medications for MSA, which primarily lessen orthostatic hypotension, parkinsonism, urinary incontinence, urinary retention, constipation, and erectile dysfunction.
Multiple System Atrophy (MSA) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA scenario of MSA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Multiple System Atrophy (MSA) Epidemiology
The epidemiology segment also provides the MSA epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Multiple System Atrophy (MSA) Drug Chapters
The drug chapter segment of the MSA report encloses the detailed analysis of MSA current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the MSA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.
Northera/DOPS (Droxidopa): Chelsea Therapeutics/Sumitomo Dainippon Pharma
Northera (droxidopa) is an oral medicine used to treat sensations of dizziness, light-headedness, and a feeling of being on the verge of passing out or fainting — all symptoms that may result from a neurological disorder like Parkinson’s disease. Northera is in a class of medications called alpha and beta-adrenergic agonists, which work by increasing norepinephrine levels. Norepinephrine is a natural circulating chemical that helps to regulate blood pressure. Northera is directly metabolized to norepinephrine by a naturally occurring enzyme called dopa-dexarboxylase. Droxidopa has been marketed in Japan since 1989. In 2014, it was approved in the US.
Products detail in the report…
Verdiperstat (AZD3241; BHV-3241): Biohaven Pharmaceuticals
Verdiperstat is a first-in-class, oral, potent, selective, brain-penetrant, and irreversible myeloperoxidase (MPO) enzyme inhibitor. Since MPO is a key driver of oxidative and inflammatory processes and is significantly increased in a range of brain disorders, it is thought that inhibiting MPO activity may be a promising therapeutic strategy for neuroinflammatory and neurodegenerative conditions, including MSA.
Verdiperstat was progressed through Phase II clinical trials by AstraZeneca. Seven clinical studies were completed by AstraZeneca, including four Phase I studies in healthy subjects, two Phase IIa studies in subjects with Parkinson’s disease, and one phase IIb study in subjects with MSA. These Phase II clinical studies provide evidence that verdiperstat achieves peripheral target engagement (i.e., reduces MPO specific activity in plasma) and central target engagement in the brain and offer proof of its mechanism of action (i.e., reduce microglial activation and neuroinflammation).
A Phase III clinical trial to evaluate the efficacy of verdiperstat in MSA is currently ongoing. The trial’s topline results are expected in the fourth quarter of 2021. The China IND approval to join the Phase III clinical trial of verdiperstat for the treatment of MSA was obtained in the fourth quarter of 2019.
In addition, Phase II/III trial to evaluate the efficacy of verdiperstat in amyotrophic lateral sclerosis (ALS) is currently ongoing as part of the HEALEY ALS platform trial.
Products detail in the report…
Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic orthostatic hypotension (nOH). It has a high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine.
Ampreloxetine showed positive 4-week results from a Phase II study in patients with nOH, including durable improvements in patients’ disease symptom severity after 4 weeks of treatment with ampreloxetine, as measured by orthostatic hypotension symptom assessment question #1 (“OHSA #1”). OHSA #1 is a measure of dizziness, lightheadedness, or the sensation of being about to blackout. Ampreloxetine is currently being evaluated in the registrational Phase III program in patients with symptomatic nOH, and the company is expecting 4-week efficacy data in 2021. The ongoing Phase 3 registrational program includes two studies, one designed to assess treatment benefit over 4 weeks and the other to assess the response’s durability.
Products detail in the report…
List to be continued in the report…
The current treatment only offers symptomatic relief. The symptomatic treatment options include medications for orthostatic hypotension, parkinsonism, urinary incontinence, urinary retention, constipation, and erectile dysfunction. No disease-modifying treatment option is currently available in the market.
The fainting and lightheadedness from orthostatic hypotension may be treated with simple interventions such as wearing compression stockings, adding extra salt and/or water to the diet, and avoiding heavy meals. The drugs fludrocortisone and midodrine sometimes are prescribed. Northera/DOPS (droxidopa) is approved in the US and Japan to treat neurogenic orthostatic hypotension seen in MSA. ProAmatine/Gutron (midodrine hydrochloride) is also approved in the US and some EU countries. ProAmatine, developed by Shire Plc – now acquired by Takeda, is discontinued in the US; however, generic versions are available in the US market.
Bladder control problems are treated according to the nature of the problem. Anticholinergic drugs, such as oxybutynin or tolterodine, may help reduce the sudden urge to urinate. Fixed abnormal muscle postures (dystonia) may be controlled with injections of botulinum toxin, and sleep problems such as REM sleep behavior disorder can be treated with medicines including clonazepam, melatonin, or some antidepressants. Some individuals with MSA may have significant difficulties with swallowing and may need a feeding tube or nutritional support. Also, speech therapy may help identify strategies to address swallowing difficulties.
Physical therapy helps maintain mobility, reduce contractures (chronic shortening of muscles or tendons around joints, preventing the joints from moving freely), and decrease muscle spasms and abnormal posture. Individuals may eventually need assistive devices such as walkers and wheelchairs. Occupational therapists help with home safety and teach new ways to address daily living activities such as dressing and eating.
Low-dose clonazepam at bedtime can be considered a treatment for a severe rapid-eye-movement sleep behavior disorder, but it may aggravate nocturnal stridor or sleep apnea. Preliminary evidence suggests that melatonin may be an alternative treatment in this situation. Cognitive impairment in patients with MSA does not usually require treatment, but pharmacologic intervention may be needed for those with severe depression, anxiety, or emotional incontinence.
Acetylcholinesterase inhibitors, such as pyridostigmine, indirectly activate muscarinic acetylcholine receptors in autonomic pathways, thus enhancing the force of bladder contractions and reducing PVR volumes. Treatment with acetylcholinesterase inhibitors can also improve postural hypotension symptoms, presumably by enhancing nicotinic acetylcholine receptor activation in the sympathetic ganglia.
The pipeline of MSA possesses potential drugs as monotherapies as well as combination therapies. Overall, the MSA therapeutics market is further expected to grow in the forecast period (2020–2030).
The United States Market Outlook
This section provides the total MSA market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total MSA market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total MSA market size and market size by therapies in Japan are provided.
Multiple System Atrophy (MSA) Drugs Uptake
This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017–2030. The analysis covers MSA market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Multiple System Atrophy (MSA) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for MSA emerging therapies.
Reimbursement Scenario in Multiple System Atrophy (MSA)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the MSA market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Multiple System Atrophy (MSA) Report Insights
Multiple System Atrophy (MSA) Report Key Strengths
Multiple System Atrophy (MSA) Report Assessment
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of Multiple System Atrophy (MSA)
3. Competitive Intelligence Analysis for Multiple System Atrophy (MSA)
4. Multiple System Atrophy (MSA) : Market Overview at a Glance
4.1. Multiple System Atrophy (MSA) Total Market Share (%) Distribution in 2017
4.2. Multiple System Atrophy (MSA) Total Market Share (%) Distribution in 2030
5. Multiple System Atrophy (MSA) : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Multiple System Atrophy (MSA) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Multiple System Atrophy (MSA) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Multiple System Atrophy (MSA) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Multiple System Atrophy (MSA) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Multiple System Atrophy (MSA) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Multiple System Atrophy (MSA) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Multiple System Atrophy (MSA) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Multiple System Atrophy (MSA) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Multiple System Atrophy (MSA) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Multiple System Atrophy (MSA) Treatment and Management
8.2. Multiple System Atrophy (MSA) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Multiple System Atrophy (MSA) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Multiple System Atrophy (MSA) : Seven Major Market Analysis
13.1. Key Findings
13.2. Multiple System Atrophy (MSA) Market Size in 7MM
13.3. Multiple System Atrophy (MSA) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Multiple System Atrophy (MSA) Total Market Size in the United States
15.1.2. Multiple System Atrophy (MSA) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Multiple System Atrophy (MSA) Total Market Size in Germany
15.3.2. Multiple System Atrophy (MSA) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Multiple System Atrophy (MSA) Total Market Size in France
15.4.2. Multiple System Atrophy (MSA) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Multiple System Atrophy (MSA) Total Market Size in Italy
15.5.2. Multiple System Atrophy (MSA) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Multiple System Atrophy (MSA) Total Market Size in Spain
15.6.2. Multiple System Atrophy (MSA) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Multiple System Atrophy (MSA) Total Market Size in the United Kingdom
15.7.2. Multiple System Atrophy (MSA) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Multiple System Atrophy (MSA) Total Market Size in Japan
15.8.3. Multiple System Atrophy (MSA) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Multiple System Atrophy (MSA)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
List of Table
Table 1 Summary of Multiple System Atrophy (MSA), Market, Epidemiology, and Key Events (2017–2030)
Table 2 Criteria for possible MSA
Table 3 Additional features of possible MSA
Table 4 Criteria for the diagnosis of probable MSA
Table 5 Features supporting (red flags) and not supporting a diagnosis of MSA
Table 6 Total Prevalence of MSA in the 7MM (2017-2030)
Table 7 Total Diagnosed Prevalence of MSA in the 7MM (2017-2030)
Table 8 Total Prevalent Cases of MSA in the United States (2017–2030)
Table 9 Total Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Table 10 Gender-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Table 11 Age-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Table 12 Type-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Table 13 Total Prevalent Cases of MSA in Germany (2017–2030)
Table 14 Total Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Table 15 Gender-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Table 16 Age-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Table 17 Type-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Table 18 Total Prevalent Cases of MSA in France (2017–2030)
Table 19 Total Diagnosed Prevalent Cases of MSA in France (2017–2030)
Table 20 Gender-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)
Table 21 Age-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)
Table 22 Type-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)
Table 23 Total Prevalent Cases of MSA in Italy (2017–2030)
Table 24 Total Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Table 25 Gender-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Table 26 Age-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Table 27 Type-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Table 28 Total Prevalent Cases of MSA in Spain (2017–2030)
Table 29 Total Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Table 30 Gender-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Table 31 Age-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Table 32 Type-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Table 33 Total Prevalent Cases of MSA in the UK (2017–2030)
Table 34 Total Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Table 35 Gender-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Table 36 Age-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Table 37 Type-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Table 38 Total Prevalent Cases of MSA in Japan (2017–2030)
Table 39 Total Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Table 40 Gender-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Table 41 Age-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Table 42 Type-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Table 43 Symptomatic treatments for MSA patients
Table 44 Treatment recommendations for MSA by American Autonomic Society and the American Academy of Neurology
Table 45 Northera/DOPS (Droxidopa), Clinical Trial Description, 2020
Table 46 Comparison of emerging drugs under development
Table 47 Verdiperstat, Clinical Trial Description, 2020
Table 48 Ampreloxetine (TD-9855), Clinical Trial Description, 2020
Table 49 Rasagiline mesylate (Azilect/TVP-1012), Clinical Trial Description, 2020
Table 50 Safinamide Methanesulfonate, Clinical Trial Description, 2020
Table 51 NBMI, Clinical Trial Description, 2020
Table 52 Key Market Forecast Assumptions for Verdiperstat
Table 53 Key Market Forecast Assumptions for Ampreloxetine
Table 54 Market Size of MSA in the 7MM in USD Million (2017–2030)
Table 55 Market Size of MSA by therapies in the 7MM, in USD Million (2017–2030)
Table 56 United States Market Size of MSA, USD Million (2017–2030)
Table 57 Market Size of MSA by therapies in the United States, in USD Million (2017–2030)
Table 58 Market Size of MSA in Germany, in USD Million (2017–2030)
Table 59 Market Size of MSA by therapies in Germany, in USD Million (2017–2030)
Table 60 Market Size of MSA in France, in USD Million (2017–2030)
Table 61 Market Size of MSA by therapies in France, in USD Million (2017–2030)
Table 62 Market Size of MSA in Italy, in USD Million (2017–2030)
Table 63 Market Size of MSA by therapies in Italy, in USD Million (2017–2030)
Table 64 Market Size of MSA in Spain, in USD Million (2017–2030)
Table 65 Market Size of MSA by therapies in Spain, in USD Million (2017–2030)
Table 66 Market Size of MSA in the UK, in USD Million (2017–2030)
Table 67 Market Size of MSA by therapies in the UK, in USD Million (2017–2030)
Table 68 Market Size of MSA in Japan, in USD Million (2017–2030)
Table 69 Market Size of MSA by therapies in Japan, in USD Million (2017–2030)
List of Figures
Figure 1 Causes of Multiple System Atrophy (MSA)
Figure 2 Subtype of MSA
Figure 3 Locating the Cerebellum and Basal Ganglia
Figure 4 Symptoms of MSA
Figure 5 Possible pathological α-Syn-spreading and accumulation mechanism leading to neurodegeneration
Figure 6 Current and future diagnostic biomarkers of MSA
Figure 7 Diagnosis of MSA
Figure 8 Diagnostic scheme for MSA according to the current consensus diagnostic criteria
Figure 9 Limitations of clinical diagnosis based on clinical signs and symptoms
Figure 10 Related Disorders
Figure 11 Patient Journey of MSA
Figure 12 Total Prevalence of MSA in the 7MM (2017-2030)
Figure 13 Total Diagnosed Prevalence of MSA in the 7MM (2017-2030)
Figure 14 Total Prevalent Cases of MSA in the United States (2017–2030)
Figure 15 Total Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)
Figure 19 Total Prevalent Cases of MSA in Germany (2017–2030)
Figure 20 Total Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Figure 21 Gender-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Figure 22 Age-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Figure 23 Type-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)
Figure 24 Total Prevalent Cases of MSA in France (2017–2030)
Figure 25 Total Diagnosed Prevalent Cases of MSA in France (2017–2030)
Figure 26 Gender-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)
Figure 27 Age-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)
Figure 28 Type-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)
Figure 29 Total Prevalent Cases of MSA in Italy (2017–2030)
Figure 30 Total Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Figure 31 Gender-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Figure 32 Age-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Figure 33 Type-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)
Figure 34 Total Prevalent Cases of MSA in Spain (2017–2030)
Figure 35 Total Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Figure 36 Gender-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Figure 37 Age-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Figure 38 Type-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)
Figure 39 Total Prevalent Cases of MSA in the UK (2017–2030)
Figure 40 Total Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Figure 41 Gender-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Figure 42 Age-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Figure 43 Type-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)
Figure 44 Total Prevalent Cases of MSA in japan (2017–2030)
Figure 45 Total Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Figure 46 Gender-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Figure 47 Age-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Figure 48 Type-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)
Figure 49 Treatment of MSA
Figure 50 Unmet Needs
Figure 51 Market Size of MSA in the 7MM in USD Million (2017–2030)
Figure 52 Market Size of MSA by Therapies in the 7MM, in USD Million (2017–2030)
Figure 53 Market Size of MSA in the United States, USD Millions (2017–2030)
Figure 54 Market Size of MSA by Therapies in the United States, USD Millions (2017–2030)
Figure 55 Market Size of MSA in Germany, USD Million (2017–2030)
Figure 56 Market Size of MSA by Therapies in Germany, in USD Million (2017–2030)
Figure 57 Market Size of MSA in France, USD Million (2017–2030)
Figure 58 Market Size of MSA by Therapies in France, in USD Million (2017–2030)
Figure 59 Market Size of MSA in Italy, USD Million (2017–2030)
Figure 60 Market Size of MSA by Therapies in Italy, in USD Million (2017–2030)
Figure 61 Market Size of MSA in Spain, USD Million(2017–2030)
Figure 62 Market Size of MSA by Therapies in Spain, in USD Million (2017–2030)
Figure 63 Market Size of MSA in the UK, USD Million (2017–2030)
Figure 64 Market Size of MSA by Therapies in the UK, in USD Million (2017–2030)
Figure 65 Market Size of MSA in Japan, USD Million (2017–2030)
Figure 66 Market Size of MSA by Therapies in Japan, in USD Million (2017–2030)
Figure 67 Market Drivers
Figure 68 Market Barriers
Figure 69 SWOT Analysis of MSA
